Oracle (ORCL) adds major banks to $20B common stock sales
Filing Impact
Filing Sentiment
Form Type
424B5
Rhea-AI Filing Summary
Oracle has a prospectus supplement covering the offer and sale of up to $20,000,000,000 of common stock from time to time through a group of investment banks acting as sales agents under an equity distribution agreement.
The supplement does not change the size of the program; it adds HSBC Securities (USA), BNP Paribas, PNC Capital Markets, SMBC Nikko, Santander US Capital Markets, TD Securities (USA), BNY Mellon Capital Markets, Credit Agricole Securities (USA), ING Financial Markets and Wells Fargo Securities as additional sales agents via a joinder agreement. Investors are directed to previously disclosed risk factors in Oracle’s earlier prospectus supplement and its Form 10‑K.
Positive
- None.
Negative
- None.
FAQ
What does Oracle (ORCL) seek to offer under this prospectus supplement?
Oracle may offer and sell up to $20,000,000,000 of common stock from time to time. The shares can be sold through multiple investment banks acting as sales agents under an existing equity distribution agreement referenced by the prospectus and this supplement.
What is the main purpose of Oracle’s February 3, 2026 prospectus supplement?
The supplement’s main purpose is to add new sales agents to Oracle’s existing common stock offering program. It updates the earlier prospectus so that additional banks can help sell shares under a joinder to the equity distribution agreement.
Which additional sales agents were added to Oracle’s equity distribution agreement?
Oracle added HSBC Securities (USA), BNP Paribas Securities, PNC Capital Markets, SMBC Nikko Securities America, Santander US Capital Markets, TD Securities (USA), BNY Mellon Capital Markets, Credit Agricole Securities (USA), ING Financial Markets and Wells Fargo Securities as additional sales agents.
Does this Oracle prospectus supplement change the $20 billion common stock amount?
The supplement does not change the stated amount of up to $20,000,000,000 of common stock. It instead modifies the list of banks that can act as sales agents under the equity distribution agreement referenced in the original prospectus.
Where can investors find the key risk factors for Oracle’s common stock offering?
Investors are directed to the “Risk Factors” section beginning on page S‑3 of the February 2, 2026 prospectus supplement and to Part I, Item 1A of Oracle’s Form 10‑K for the fiscal year ended May 31, 2025.
Has any regulator approved the Oracle common stock described in this supplement?
No regulator has approved or disapproved these securities. The supplement states that neither the U.S. Securities and Exchange Commission nor any state securities commission has determined whether the prospectus supplement or the accompanying prospectus is truthful or complete.